新普京澳门娱乐场网站-www.1166.com-Online Entrance

  • Becoming a global leader in structural heart disease

  1. 1
  2. 2
  • Becoming a global leader in structural heart disease

  1. 1
  2. 2

Company Overview

---------

Founded in 2009, Venus Medtech is located in Hangzhou National High-Tech Industrial Development Zone (Binjiang) and is committed to the development and industrialization of transcatheter therapy products for structural heart disease. On December 10th, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (SEHK) with stock code 02500.

The company's all series of “China Intelligently Manufactured " valves has been introduced to more than 50 countries and regions worldwide, including Asia, Europe, South America. Venus Medtech has established comprehensive solutions for structural heart disease, with a complete product pipeline covering all four heart valves, namely TAVR, TPVR, TMVR and TTVR, as well as hypertrophic cardiomyopathy, hypertensive renal denervation (RDN) therapy and relevant accessory products.

  • +

    +

    Employees

  • +

    Patent applications

  • > RMB

    million

    invested in R&D avg per year

  • +

    Real-world implantation cases

  • years

    The longest duration of clinical follow-up

  • +

    Centers nationwide

  • .43%

    Proportion of immediate safe surgery

As of Dec 2023

Global landscape


Thailand

Malaysia

India

Pakistan

Europe

Austria,Belgium,Netherlands,Italy,Spain,Portugal,Denmark,Poland,Switzerland,UK,Greece,Finland,Cyprus,Hungary,Sweden,Norway,Germany,France,Ireland,Turkey,Monaco,Bulgaria,Croatia,Czech Republic,Lithuania,Romania,Slovakia,Slovenia,Estonia,Latvia,Luxemburg,Malta,Iceland,Liechtenstein

Canada

Brazil

Chile

Argentina

HKSAR

Macao SAR

Uruguay

Colombia

Middle East

Dubai,Saudi Arabia,Jordan,Qatar,Egypt,Morocco,Bahrain

Kyrgyzstan

Kazakhstan

Venezuela

Australia